The Latest Breaking News from Abbott

Along with much of the globe, US consumers are reeling from a cost of living and supply-chain crisis. One example is a shortage of baby formula caused by a constellation of factors, from rampant inflation to a massive recall over safety concerns.

Parents across the U.S. are scrambling to find baby formula because of supply disruptions and a massive safety recall by manufacturer Abbott

Since the persistent Ukraine-Russia war, rising inflationary pressures, and Fed's upcoming interest rate hikes are expected to keep the stock market volatile in the near term, investors seek opportunities to invest in large-cap stocks, which hold the potential to generate relatively stable returns. So, we think it could be wise…

Raymond James thinks Abbott Laboratories' (NYSE: ABT) 1Q results were solid and demonstrated the durable nature of ABT's portfolio, as three out of four business segments grew over 10% organically, with Nutrition growing 8% 

Abbott Laboratories (NYSE:ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion. Worldwide sales, excluding…

Out-of-stock per centages reached higher than 40 per cent in seven states in first week of April

Product recalls after illnesses and deaths linked to powdered infant formula products combine with supply chain problems

Justice Department urged to investigate after watchdog group found DeJoy owns stock in Abbott Laboratories

An inspection at the Abbott Laboratories (NYSE: ABT) facility in Sturgis, Michigan,